Valuation: Freenome, Inc.

Market Cap 1.37B 1.22B 1.13B 1.03B 1.92B 130B 1.95B 13.62B 5.39B 68.18B 5.15B 5.04B 215B P/E 2026 *
-6.48x
P/E 2027 * -5.72x
Enterprise Value 1.37B 1.22B 1.13B 1.03B 1.92B 130B 1.95B 13.62B 5.39B 68.18B 5.15B 5.04B 215B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 12.1x
Free-Float
74.05%
Yield 2026 *
-
Yield 2027 * -
1 day+11.85%
1 week+19.66%
Current month-10.73%
1 month-10.45%
3 months+15.25%
6 months+24.42%
Current year+7.90%
1 week 11.79
Extreme 11.79
14.42
1 month 11.63
Extreme 11.63
17.3
Current year 9.95
Extreme 9.95
17.5
1 year 9.95
Extreme 9.95
17.5
3 years 9.95
Extreme 9.95
17.5
5 years 9.95
Extreme 9.95
17.5
10 years 9.95
Extreme 9.95
17.5
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Tax

Chief Executive Officer

-71,920 0.0669%
7/20/26 Other

Chief Executive Officer

835,791 0.3889%
7/20/26 Conversion -30,000 1.3913%
Change 5-day change 1-year change 3-year change Capi.($)
+11.85%+19.66%+31.65% - 1.37B
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +1.43%+3.71%+47.72%+157.55% 38.45B
Weighted average by Cap. +0.43%+2.78%+47.51%+158.58%

Financials

2026 *2027 *
Net sales 102M 91.43M 84.4M 76.59M 143M 9.72B 146M 1.02B 402M 5.09B 384M 376M 16.06B 114M 102M 93.81M 85.13M 159M 10.81B 162M 1.13B 447M 5.66B 427M 418M 17.85B
Net income -175M -156M -144M -131M -245M -16.63B -249M -1.74B -688M -8.7B -657M -643M -27.46B -246M -219M -203M -184M -344M -23.33B -349M -2.44B -965M -12.21B -922M -903M -38.54B
Net Debt - -
Projected Income Statement - Annual - Freenome, Inc.
Logo Freenome, Inc.
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.
Employees
378
Date Price Change Volume
26-10-23 US$12.77 -2.52% 612,770
26-10-22 US$13.10 -6.50% 586,697
26-10-21 US$14.01 -0.36% 381,705
26-10-20 US$14.06 +11.85% 860,694
26-10-19 US$12.57 +6.98% 649,374
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.77USD
Average target price
18.00USD
Spread / Average Target
+40.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Freenome, Inc.
  1. Stock Market
  2. Stocks
  3. FRNM Stock